

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 11/30/2011. OMB 0881-0036
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number:

051957

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number:

051957

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Email		

Assignee Name and Address:

Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/98 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature	<i>Debra D. Condino</i>	Date	5/15/2011
Name	Debra D. Condino	Telephone	(714) 246-2388
Title	Assistant Secretary		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

MAY 16 2011

17615 (AP)

PTO/SB/96 (01-08)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Allergan, Inc.Application No./Patent No.: 6887896 Filed/Issue Date: 05/03/2005Entitled: 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITYALLERGAN, INC., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

In the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 014660, Frame 0458, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Debra D. Condino
Signature5/15/2011
DateDebra D. Condino
Printed or Typed Name714.246.2388
Telephone NumberAssistant Secretary
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006887896B1

(12) **United States Patent**
Beard et al.

(10) Patent No.: **US 6,887,896 B1**
(45) Date of Patent: **May 3, 2005**

(54) **7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY**

(75) Inventors: **Richard L. Beard**, Newport Beach, CA (US); **Tien T. Duong**, Irvine, CA (US); **Janet A. Tukeuchi**, Anaheim, CA (US); **Ling Li**, Irvine, CA (US); **Kwok Yin Tsang**, Irvine, CA (US); **Xiaoxia Liu**, Tustin, CA (US); **Jayasree Vasudevan**, Anaheim, CA (US); **Liming Wang**, Irvine, CA (US); **Santosh C. Sinha**, Irvine, CA (US); **Haigqing Yuan**, Irvine, CA (US); **Roshantha A. Chandraratna**, Laguna Hills, CA (US)

(73) Assignee: **Allergan, Inc.**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/696,748**

(22) Filed: **Oct. 29, 2003**

(51) Int. Cl.⁷ **A61K 31/35; A61K 31/235; A61K 31/19**

(52) U.S. Cl. **514/456; 514/532; 514/569; 560/56; 562/466**

(58) Field of Search **549/399, 407; 560/56; 562/466; 514/456, 532, 569**

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,445,265 A	8/1995	Herr et al.
5,667,320 A	9/1997	Ambrose et al.
5,721,103 A	2/1998	Boehm et al.
5,801,253 A	9/1998	Klaus et al.
5,917,082 A	6/1999	Vuligonda et al.
6,048,873 A	4/2000	Vasudevan et al.
6,114,533 A	9/2000	Vuligonda et al.
6,147,224 A	11/2000	Vuligonda et al.

6,326,397 B1 12/2001 Bollag et al.

6,613,917 B1 9/2003 Beard et al.

FOREIGN PATENT DOCUMENTS

WO WO 93/11755 6/1993

WO WO 97/12853 4/1997

WO WO 01/19770 3/2001

OTHER PUBLICATIONS

Mangelsdorf, et al., *The Retinoid Receptors*, The Retinoids, 1994, 319-349, Raven Press, Ltd., New York.

Dawson, et al., *Chemistry and Biology of Synthetic Retinoids*, 1990, 324-356, CRC Press, Inc.

Mukherjee, et al., *Sensitization of Diabetic and Obese Mice to Insulin by retinoid X Receptor Agonists*, *Nature*, 1997, 407-410, 386.

Feiguer, et al., *Focus*, 1989, 21-25, 11, 2.

Heyman, et al., *Cell*, 1992, 397-406, 68.

Cheng, et al., *Biochemical Pharmacology*, 1973, 3099-3108, 22.

Allegretto, et al., *Transactivation Properties of Retinoic acid and Retinoid X Receptors in Mammalian Cells and Yeast*, 1993, 26625-26633, 268, 35.


Piers, et al., *Synthesis*, 1995, 47-55.

Primary Examiner—Amelia A. Owens

(74) *Attorney, Agent, or Firm*—Gabor L. Szekeres

(57) **ABSTRACT**

Compounds of the formula



where the variations have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.

68 Claims, No Drawings



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)



Assignments on the Web > Patent Query

Patent Assignment Abstract of Title

NOTE: Results display only for issued patents and applications.